StemRIM
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/08/01Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | |
|---|---|---|
| Income Statement | ||
| Revenue | ¥23M | ¥2,350M |
| Gross Profit | - | - |
| Operating Income | -¥1,981M | ¥142M |
| Pretax Income | -¥1,946M | ¥170M |
| Net Income | -¥1,948M | ¥168M |
| EPS | -¥32.92 | ¥2.69 |
| Operating Margin | -8,620.68% | 6.06% |
| Balance Sheet | ||
| Total Assets | ¥9,597M | ¥10,706M |
| Total Equity | ¥9,405M | ¥10,370M |
| Total Liabilities | ¥192M | ¥336M |
| Cash | ¥8,880M | ¥10,218M |
| Interest-bearing Debt | ¥4M | ¥1M |
| Equity Ratio | 97.99% | 96.86% |
| D/E Ratio | 0.00 | 0.00 |
| Cash Flow | ||
| Operating CF | -¥1,405M | ¥1,135M |
| Investing CF | -¥0M | -¥0M |
| Financing CF | ¥113M | ¥203M |
| Free CF | -¥1,405M | ¥1,135M |
| Efficiency | ||
| ROE | -20.72% | 1.62% |
| ROA | -20.30% | 1.57% |
Latest IR Information
-
Patent registration (Development Code: SR-GT1) for stem cell gene therapy technology aimed at curing hereditary epidermolysis bullosa (Korea)
Notice of patent registration in Korea for SR-GT1, a stem cell gene therapy technology targeting treatment of hereditary epidermolysis bullosa. Filing region: Korea; application number unspecified. Description notes progress toward clinical application.
Read more -
Patent Registration and Business Expansion for Regenerative Induction Drugs | July 2026
StemRim has registered a patent in Mexico for the use of regenerative induction drug Redasemtide in cartilage disorders, indicating potential for future business expansion and medical applications. It is not expected to have a direct impact on the full-year financial...
Read more -
【StemRim】Canada Patent Registration and Development of Heart Failure Treatment｜July 2026
StemRim announced the registration of a patent in Canada for Ledasemide, aiming to expand its application to cardiomyopathy and heart failure. Since March 2024, a Phase II physician-led clinical trial has been initiated with Osaka University Graduate School of Medicine.
Read more -
StemRIM: Notice of Patent Registration for Stem Cell Gene Therapy Technology SR-GT1 Aiming to Cure Nutritional Epidermolysis Bullosa
Notice of patent registration for the stem cell gene therapy technology SR-GT1 related to treatment for nutritional epidermolysis bullosa completed in Korea. Disclosure of basic information such as invention title, jurisdiction, application number, and applicant.
Read more -
Notice Regarding Recognition of Non-Operating Income (Subsidy Revenue)
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥700
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
